• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form FWP filed by Becton Dickinson and Company

    5/11/26 4:26:45 PM ET
    $BDX
    Medical/Dental Instruments
    Health Care
    Get the next $BDX alert in real time by email
    FWP 1 ny20072670x2_fwp.htm FWP
    Filed pursuant to Rule 433
    Issuer Free Writing Prospectus dated May 11, 2026 Supplementing the Preliminary Prospectus Supplement dated May 11, 2026
    Registration Statement No. 333-279084-01
    333-279084

    PRICING TERM SHEET
    Becton Dickinson Euro Finance S.à r.l.
    €600,000,000 3.855% Notes due 2033
    (the “Notes”)


    Fully and Unconditionally Guaranteed by
    Becton, Dickinson and Company

    Issuer:
    Becton Dickinson Euro Finance S.à r.l. (the “Company”)
       
    Guarantor:
    Becton, Dickinson and Company (the “Guarantor”)
       
    Aggregate Principal Amount Offered:
    €600,000,000
       
    Maturity Date:
    May 20, 2033
       
    Trade Date:
    May 11, 2026
       
    Settlement Date:
    May 20, 2026 (T+7)*
       
    Type of Offering:
    SEC Registered
       
    Coupon (Interest Rate):
    3.855%
       
    Price to Public (Issue Price):
    100.000% of principal amount
       
    Underwriting Discount:
    0.400%
       
    Yield to Maturity:
    3.855%
       
    Spread to Benchmark German Government Security:
    +100.9 basis points
     
    Benchmark German Government Security:
    2.300% DBR due February 15, 2033
       
    Benchmark German Government Security Price/Yield:
    96.680% / 2.846%
       
    Mid-Swap Yield:
    2.925%
       
    Spread to Mid-Swap Yield:
    +93 basis points
       
    Interest Payment Dates:
    Annually, May 20, commencing May 20, 2027
       
    Day Count Convention:
    ACTUAL/ACTUAL (ICMA)



    Optional Redemption:
    The Notes will be redeemable at the Company’s option, in whole or in part, at any time and from time to time prior to February 20, 2033 (three months prior to the maturity date), at a redemption price equal to the greater of (1) 100% of the principal amount of the Notes to be redeemed and (2) the sum of the present values of the remaining scheduled payments on the Notes being redeemed, discounting such payments to the redemption date on an annual basis (ACTUAL/ACTUAL (ICMA)) at the applicable comparable government bond rate, plus 15 basis points, plus, in each case, accrued and unpaid interest thereon to, but excluding, the redemption date.
     
    At any time on or after February 20, 2033 (three months prior to the maturity date), the Notes will be redeemable at the Company’s option, in whole or in part, at any time and from time to time, at a redemption price equal to 100% of the principal amount of the Notes to be redeemed, plus accrued and unpaid interest thereon to, but excluding, the redemption date.
     
       
    Redemption for Tax Reasons:
    If, as a result of any change in, or amendment to, the tax laws of a Taxing Jurisdiction (as defined in the preliminary prospectus supplement), or the official interpretation thereof, the Company becomes or, based upon a written opinion of independent counsel selected by the Company, will become obligated to pay additional amounts with respect to the Notes, the Company may at any time at its option redeem, in whole, but not in part, the Notes at 100% of the principal amount plus accrued and unpaid interest to the date of redemption.
       
    Change of Control:
    If a change of control triggering event occurs, unless the Company has exercised its right to redeem the Notes as described under “Optional Redemption,” the Company will be required to make an offer to each holder of the outstanding Notes to repurchase all or any portion of such holder’s Notes at a purchase price of 101% of the principal amount plus accrued and unpaid interest to, but excluding, the date of purchase.
       
    Form/Clearing Systems:
    The Notes will be issued only in registered, book-entry form. There will be a global Note for each series of Notes deposited with a common safekeeper for Euroclear and Clearstream.
       
    Listing:
    Application will be made to have the Notes listed on the New York Stock Exchange.
       
    New Safekeeping Structure:
    Yes, and the notes are intended to be held in a manner that would allow eligibility as collateral for Eurosystem intra-day credit and monetary policy operations
       
    MiFID II Product Governance:
    Manufacturer target market (MiFID II product governance) is eligible counterparties and professional clients only (all distribution channels)
       
    UK MiFIR Product Governance:
    Manufacturer target market (UK MiFIR product governance) is eligible counterparties and professional clients only (all distribution channels)

    2


    PRIIPs:
    No EEA PRIIPs key information document (KID) or UK PRIIPs KID/CCI product summary has been prepared as not available to retail in EEA or UK.
       
    Common Code/ISIN:
    336884934 / XS3368849348
       
    Denominations:
    €100,000 x €1,000
       
    Stabilization:
    ICMA/FCA
       
    Joint Book-Running Managers:
    Barclays Bank PLC (Stabilization Manager)
    BNP PARIBAS
    Goldman Sachs & Co. LLC
    Morgan Stanley & Co. International plc
       
    Passives:
    MUFG Securities (Europe) N.V.
    Scotiabank (Ireland) Designated Activity Company
    U.S. Bancorp Investments, Inc.
       
    Co-Managers:
    Academy Securities, Inc.
    Banco Santander, S.A.
    ING Bank N.V., Belgian branch
    Intesa Sanpaolo IMI Securities Corp.
    Loop Capital Markets LLC
    Siebert Williams Shank & Co., LLC
    Standard Chartered Bank
    TD Global Finance unlimited company
     
     


    *
    Under Rule 15c6-1 under the Securities Exchange Act of 1934, trades in the secondary market generally are required to settle in one business day, unless the parties to any such trade expressly agree otherwise. Accordingly, purchasers who wish to trade the Notes prior to the business day preceding the settlement date will be required, by virtue of the fact that the Notes initially settle on the third business day following the Trade Date, to specify an alternate settlement arrangement at the time of any such trade to prevent a failed settlement. Purchasers of the Notes who wish to trade the Notes prior to their date of delivery hereunder should consult their advisors.
    3

    The Guarantor and the Issuer have filed a registration statement with the SEC (including a prospectus and a preliminary prospectus supplement), for the offering to which this communication relates. Before you invest, you should read the prospectus and the preliminary prospectus supplement in that registration statement and other documents the Guarantor and the Issuer have filed with the SEC for more complete information about the Guarantor, the Issuer and this offering. You may get these documents for free by visiting EDGAR on the SEC Web site at http://www.sec.gov. Alternatively, the Issuer, the Guarantor, any underwriter or any dealer participating in the offering will arrange to send you the prospectus if you request it by contacting Barclays Bank PLC toll-free at +1 888-603-5847, BNP PARIBAS toll-free at +44 0-20-7595-8222, Goldman Sachs & Co. LLC toll-free at +1-866-718-1649 or Morgan Stanley & Co. International plc toll-free at +1-866-718-1649.
    This pricing term sheet supplements the preliminary prospectus supplement dated May 11, 2026 relating to the prospectus dated May 11, 2026.  Capitalized terms used in this term sheet but not defined herein have the meanings given to them in the preliminary prospectus supplement.
    MiFID II and/or the UK MiFIR Product Governance Rules professionals/ECPs-only / No PRIIPs KID – Manufacturer target market (MIFID II product governance and/or the UK MiFIR Product Governance Rules) is eligible counterparties and professional clients only (all distribution channels). No EU PRIIPs key information document (KID) and no UK disclosure document required by DISC have been prepared as the notes are not available to retail in EEA or UK.
    Any disclaimers or other notices that may appear below are not applicable to this communication and should be disregarded. Such disclaimers or other notices were automatically generated as a result of this communication being sent via Bloomberg or another email system.

    4
    Get the next $BDX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BDX

    DatePrice TargetRatingAnalyst
    5/4/2026$180.00Outperform
    Evercore ISI
    4/10/2026$167.00Neutral
    Goldman
    2/10/2026$202.00Overweight
    Barclays
    2/3/2026$233.00Buy
    Citigroup
    9/25/2025$211.00Sector Perform
    RBC Capital Mkts
    5/22/2025$185.00Buy → Neutral
    Citigroup
    5/2/2025$185.00Overweight → Neutral
    Piper Sandler
    5/2/2025$192.00Buy → Neutral
    Goldman
    More analyst ratings

    $BDX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    BD Delivers Kidney Stone Care for Urology Teams with the Elyra™ Thulium Fiber Laser System

    New laser system is designed to help urology teams enhance efficiency, versatility, and procedural workflow across stone management and soft tissue procedures.FRANKLIN LAKES, N.J., May 21, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced the introduction of the Elyra™ Thulium Fiber Laser (TFL) System, an advanced laser platform developed to complete BD's kidney stone care portfolio for urology teams. Designed to enhance efficiency, versatility, and procedural workflow across urologic stone management and soft tissue procedures, the innovative new system supports consistent performance in demanding clinical enviro

    5/21/26 6:50:00 AM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    Peter Menziuso Named EVP and President, BD Interventional

    FRANKLIN LAKES, N.J., May 18, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced that Peter Menziuso has been named executive vice president and president, BD Interventional, effective June 1. Menziuso brings more than 30 years of global healthcare leadership experience and a strong track record of driving growth through disciplined execution. He most recently served as Company Group Chairman of Johnson & Johnson Vision, where he led a $5 billion global business with responsibility for commercial opera

    5/18/26 6:50:00 AM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    BD Appoints Vitor Roque Chief Financial Officer

    FRANKLIN LAKES, N.J., May 7, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced that Vitor Roque has been named executive vice president and chief financial officer (CFO), effective May 7. Roque has served as interim CFO since December 2025. With more than 25 years at BD, Roque has held senior finance and operations roles across the company, most recently as senior vice president, Finance and Corporate Financial Planning and Analysis. During his tenure as interim CFO, he led BD's global finance functio

    5/7/26 6:31:00 AM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    $BDX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Evercore ISI resumed coverage on Becton Dickinson with a new price target

    Evercore ISI resumed coverage of Becton Dickinson with a rating of Outperform and set a new price target of $180.00

    5/4/26 8:48:11 AM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    Goldman resumed coverage on Becton Dickinson with a new price target

    Goldman resumed coverage of Becton Dickinson with a rating of Neutral and set a new price target of $167.00

    4/10/26 12:23:31 PM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    Barclays resumed coverage on Becton Dickinson with a new price target

    Barclays resumed coverage of Becton Dickinson with a rating of Overweight and set a new price target of $202.00

    2/10/26 7:21:54 AM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    $BDX
    SEC Filings

    View All

    Becton Dickinson and Company filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - BECTON DICKINSON & CO (0000010795) (Filer)

    5/29/26 8:39:28 AM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    SEC Form SD filed by Becton Dickinson and Company

    SD - BECTON DICKINSON & CO (0000010795) (Filer)

    5/22/26 1:24:24 PM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    SEC Form CERT filed by Becton Dickinson and Company

    CERT - BECTON DICKINSON & CO (0000010795) (Filer)

    5/21/26 1:18:51 PM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    $BDX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chairman, CEO and President Polen Thomas E Jr exercised 20,209 shares at a strike of $126.16, returned $2,549,587 worth of shares to the company (17,445 units at $146.15) and sold $404,511 worth of shares (2,764 units at $146.35) as part of a pre-agreed trading plan, increasing direct ownership by 4% to 110,163 units (SEC Form 4)

    4 - BECTON DICKINSON & CO (0000010795) (Issuer)

    6/3/26 12:44:24 PM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    EVP and President, BDI Menziuso Peter was granted 14,258 shares (SEC Form 4)

    4 - BECTON DICKINSON & CO (0000010795) (Issuer)

    6/2/26 2:11:50 PM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    New insider Menziuso Peter claimed no ownership of stock in the company (SEC Form 3)

    3 - BECTON DICKINSON & CO (0000010795) (Issuer)

    6/2/26 2:04:55 PM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    $BDX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Hayes Gregory bought $1,005,742 worth of shares (5,250 units at $191.57), increasing direct ownership by 660% to 6,046 units (SEC Form 4)

    4 - BECTON DICKINSON & CO (0000010795) (Issuer)

    8/11/25 4:15:55 PM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    Director Henderson Jeffrey William bought $350,430 worth of shares (1,500 units at $233.62), increasing direct ownership by 23% to 8,015 units (SEC Form 4)

    4 - BECTON DICKINSON & CO (0000010795) (Issuer)

    2/10/25 5:03:18 PM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    $BDX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    November 23, 2021 - Coronavirus (COVID-19) Update: November 23, 2021

    For Immediate Release: November 23, 2021 The U.S. Food and Drug Administration today announced the following actions taken in its ongoing response effort to the COVID-19 pandemic: On Nov. 22, the FDA authorized three over-the-counter (OTC) COVID-19 antigen diagnostic tests for people age 14 years or older with a self-collected nasal swab sample or people age 2 years or older when an adult collects the nasal swa

    11/23/21 3:16:12 PM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    July 23, 2021 - Coronavirus (COVID-19) Update: July 23, 2021

    For Immediate Release: July 23, 2021 The U.S. Food and Drug Administration today announced the following actions taken in its ongoing response effort to the COVID-19 pandemic: The agency updated its FDA COVID-19 Response At-A-Glance Summary, which provides a quick look at facts, figures and highlights on the FDA's response efforts. On Thursday, July 22 the FDA issued an Emergency Use Authorization (EUA) to Bec

    7/23/21 4:06:11 PM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    $BDX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Becton Dickinson and Company (Amendment)

    SC 13G/A - BECTON DICKINSON & CO (0000010795) (Subject)

    2/16/24 4:29:42 PM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by Becton Dickinson and Company (Amendment)

    SC 13G/A - BECTON DICKINSON & CO (0000010795) (Subject)

    2/14/24 10:02:59 AM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by Becton Dickinson and Company (Amendment)

    SC 13G/A - BECTON DICKINSON & CO (0000010795) (Subject)

    2/13/24 5:00:53 PM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    $BDX
    Financials

    Live finance-specific insights

    View All

    BD Reports Second Quarter Fiscal 2026 Financial Results

    Revenue of $4.7 billion increased 5.2% as reported, 2.6% FXNGAAP and adjusted diluted EPS from continuing operations of $(0.13) and $2.90, respectivelyExecuted a $2.0 billion accelerated share repurchase (ASR) program and retired $2.1 billion of debt in the quarterCompany reaffirms revenue growth guidance, raises full-year adjusted diluted EPS guidance1FRANKLIN LAKES, N.J., May 7, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced results for its fiscal 2026 second quarter, which ended March 31, 2026. "We delivered a solid second quarter, with revenue, margins and EPS all ahead of our expectations," said Tom Polen,

    5/7/26 6:30:00 AM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    BD Board Declares Dividend

    FRANKLIN LAKES, N.J., April 28, 2026 /PRNewswire/ -- The Board of Directors of BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced it has declared a quarterly dividend of $1.05 per common share, payable on June 30, 2026, to holders of record on June 9, 2026. The indicated annual dividend rate is $4.20 per share. About BDBD is one of the world's largest pure-play medical technology companies with a Purpose of advancing the world of health™ by driving innovation across medical essentials, connected care, biopharma systems and interventional. The company supports those on the frontlines of healthcare by developing transformative technologi

    4/28/26 4:15:00 PM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    BD Reports First Quarter Fiscal 2026 Financial Results

    Revenue of $5.3 billion increased 1.6% as reported, 0.4% FXNNew BD revenue increased 2.5% FXNGAAP and adjusted diluted EPS of $1.34 and $2.91, respectivelyCombination of BD's Biosciences and Diagnostic Solutions business with Waters Corporation expected to close todayCompany affirms FY26 revenue growth guidance, provides Adjusted Diluted EPS guidance for New BDFRANKLIN LAKES, N.J., Feb. 9, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced results for its fiscal 2026 first quarter, which ended December 31, 2025. "We delivered stronger‑than‑expected first‑quarter performance which reflects our disciplined execution

    2/9/26 6:30:00 AM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    $BDX
    Leadership Updates

    Live Leadership Updates

    View All

    BD Appoints Vitor Roque Chief Financial Officer

    FRANKLIN LAKES, N.J., May 7, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced that Vitor Roque has been named executive vice president and chief financial officer (CFO), effective May 7. Roque has served as interim CFO since December 2025. With more than 25 years at BD, Roque has held senior finance and operations roles across the company, most recently as senior vice president, Finance and Corporate Financial Planning and Analysis. During his tenure as interim CFO, he led BD's global finance functio

    5/7/26 6:31:00 AM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    Waters Completes Combination with BD's Biosciences & Diagnostic Solutions Businesses

    Announces appointment of Claire M. Fraser, Ph.D., to its Board of DirectorsForms a global life sciences and diagnostics leader focused on high-volume testing in regulated applicationsAnnounces formation of four divisions: Waters Analytical Sciences, Waters Biosciences, Waters Advanced Diagnostics, and Waters Materials SciencesMILFORD, Mass., Feb. 9, 2026 /PRNewswire/ -- Waters Corporation (NYSE:WAT) ("Waters") today announced it has completed the previously announced combination with the Biosciences & Diagnostic Solutions businesses of Becton, Dickinson and Company (NYSE:BDX) ("BD"). The transaction forms a global life sciences and diagnostics leader, equipped with best-in-class technologies

    2/9/26 8:40:00 AM ET
    $BDX
    $WAT
    Medical/Dental Instruments
    Health Care
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    BD Appoints Robert Huffines and Jacqueline Wright to Board of Directors

    FRANKLIN LAKES, N.J., Nov. 17, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced the appointment of Robert "Robbie" Huffines and Jacqueline "Jacky" Wright to its board of directors, effective Dec. 1, 2025. "Robbie and Jacky will further strengthen the BD board with deep expertise in health care, technology, digital transformation and artificial intelligence, as well as finance and capital markets, all of which are core to the continued advancement of our strategy," said Tom Polen, chairman, CEO and

    11/17/25 4:30:00 PM ET
    $BDX
    Medical/Dental Instruments
    Health Care